JP2025517106A - Parp1阻害剤としての化合物 - Google Patents

Parp1阻害剤としての化合物 Download PDF

Info

Publication number
JP2025517106A
JP2025517106A JP2024563976A JP2024563976A JP2025517106A JP 2025517106 A JP2025517106 A JP 2025517106A JP 2024563976 A JP2024563976 A JP 2024563976A JP 2024563976 A JP2024563976 A JP 2024563976A JP 2025517106 A JP2025517106 A JP 2025517106A
Authority
JP
Japan
Prior art keywords
compound
group
alkyl
cancer
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517106A5 (cg-RX-API-DMAC10.html
Inventor
ワン,ティンジョン
シェン,ジェンハイ
ピー エイ タルボット,エリック
エム ベイトマン,ジョセフ
エフ ラヘムトゥラ,ベンジャミン
モロール,ムスタファ
ラデォワヘッティ,タミー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ningbo Newbay Technology Development Co Ltd
Original Assignee
Ningbo Newbay Technology Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningbo Newbay Technology Development Co Ltd filed Critical Ningbo Newbay Technology Development Co Ltd
Publication of JP2025517106A publication Critical patent/JP2025517106A/ja
Publication of JP2025517106A5 publication Critical patent/JP2025517106A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024563976A 2022-04-28 2023-02-20 Parp1阻害剤としての化合物 Pending JP2025517106A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/089986 2022-04-28
CN2022089986 2022-04-28
PCT/CN2023/077272 WO2023207283A1 (en) 2022-04-28 2023-02-20 Compounds as parp1 inhibitiors

Publications (2)

Publication Number Publication Date
JP2025517106A true JP2025517106A (ja) 2025-06-03
JP2025517106A5 JP2025517106A5 (cg-RX-API-DMAC10.html) 2026-02-27

Family

ID=88517229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563976A Pending JP2025517106A (ja) 2022-04-28 2023-02-20 Parp1阻害剤としての化合物

Country Status (6)

Country Link
US (1) US20250289814A1 (cg-RX-API-DMAC10.html)
EP (1) EP4514795A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025517106A (cg-RX-API-DMAC10.html)
KR (1) KR20250033148A (cg-RX-API-DMAC10.html)
CN (1) CN119487027A (cg-RX-API-DMAC10.html)
WO (1) WO2023207283A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
TW202416977A (zh) * 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途
KR20260100685A (ko) * 2023-10-23 2026-06-30 길리애드 사이언시즈, 인코포레이티드 Parp1 저해제 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0906294T1 (en) * 1996-05-29 2003-04-30 Warner-Lambert Company Benzoxazinone dopamine d4 receptor antagonists
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
EP1758895A1 (en) * 2004-06-17 2007-03-07 Wyeth a Corporation of the State of Delaware Gonadotropin releasing hormone receptor antagonists
WO2009053373A1 (en) * 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2415767B1 (en) * 2009-03-27 2014-09-03 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) Polymerase (PARP) Inhibitors
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
WO2022228387A1 (en) 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
TW202416977A (zh) 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途

Also Published As

Publication number Publication date
EP4514795A4 (en) 2025-12-31
KR20250033148A (ko) 2025-03-07
US20250289814A1 (en) 2025-09-18
EP4514795A1 (en) 2025-03-05
WO2023207283A1 (en) 2023-11-02
CN119487027A (zh) 2025-02-18

Similar Documents

Publication Publication Date Title
US11591331B2 (en) PARP1 inhibitors and uses thereof
JP7680619B2 (ja) Parp1阻害薬及びその使用
KR102903399B1 (ko) 트리시클릭 parp1 저해제 및 이의 용도
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
KR20200011965A (ko) Map4k1의 신규한 억제제
KR20250033148A (ko) Parp1 억제제로서의 화합물
JP6646044B2 (ja) キナーゼ阻害剤としての化合物および組成物
WO2023146957A1 (en) Parp1 inhibitors and uses thereof
JP2025503116A (ja) Parp1阻害薬及びその使用
TW202341987A (zh) 一種Polθ抑制劑
CA3179671A1 (en) Kinase inhibitors and uses thereof
CN110078730B (zh) 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物
JP2024527565A (ja) Map4k1阻害物質として使用するためのピリミジン化合物
HK40124295B (en) Tricyclic parp1 inhibitors and uses thereof
HK40124295A (en) Tricyclic parp1 inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260218